Aydın Ersin, Tekeli Hakan, Karabacak Ercan, Altunay İlknur Kıvanç, Aydın Çigdem, Çerman Aslı Aksu, Altundağ Aytuğ, Salihoğlu Murat, Çayönü Melih
Department of Dermatology, Kasimpasa Military Hospital, Beyoglu, 34440, Istanbul, Turkey.
Department of Norology, GATA Haydarpasa Training Hospital, Istanbul, Turkey.
Arch Dermatol Res. 2016 Aug;308(6):409-14. doi: 10.1007/s00403-016-1662-7. Epub 2016 Jun 14.
It is well known that psoriasis is not only limited to skin, but a systemic autoimmune disease with various comorbidities. Olfactory dysfunction, one of as a common but lesser known symptom of patients with autoimmune diseases, often presents with smell loss. The aim of this study was to assess the olfactory functions in patients with psoriasis and to compare with healthy controls. A total of 50 patients with psoriasis and 43 control subjects were included to the study. The clinical severity of psoriasis was calculated by psoriasis area and severity index (PASI). Patients were classified into two groups according to PASI score as mild (PASI ≤10) and moderate-severe (PASI >10). Olfactory function was evaluated with "Sniffin'Sticks" test. Total test scores (max. 48 points) of threshold, discrimination, and identification (TDI) were classified as normal olfaction = normosmia (>30.3 points), decreased olfaction = hyposmia (16.5-30.3 points) and loss of olfaction = anosmia (<16.5 points). Psoriasis patients had significantly lower smell scores compared with healthy controls (p < 0.001). Of the 50 psoriasis patients, 40 (80 %) were hyposmic. We found negative correlation between TDI and PASI (r = -0.34, p = 0.014). The TDI scores of the patients with moderate-severe psoriasis (PASI score >10) were found to be significantly lower than the patients with mild psoriasis (PASI ≤10) (p < 0.001). Olfactory dysfunction in patients with psoriasis could be thought as a comorbidity as in other inflammatory disorders. Physicians should be aware of olfactory impairment when evaluating psoriasis patients in their clinical practice.
众所周知，银屑病不仅局限于皮肤，而是一种伴有多种合并症的系统性自身免疫性疾病。嗅觉功能障碍是自身免疫性疾病患者常见但鲜为人知的症状之一，常表现为嗅觉丧失。本研究的目的是评估银屑病患者的嗅觉功能，并与健康对照者进行比较。共有50例银屑病患者和43名对照者纳入本研究。银屑病的临床严重程度通过银屑病面积和严重程度指数（PASI）计算。根据PASI评分将患者分为两组，轻度（PASI≤10）和中度至重度（PASI>10）。用“嗅觉棒”测试评估嗅觉功能。阈值、辨别和识别（TDI）的总测试分数（最高48分）分类如下：嗅觉正常=嗅觉正常（>30.3分），嗅觉减退=嗅觉减退（16.5 - 30.3分），嗅觉丧失=嗅觉缺失（<16.5分）。与健康对照者相比，银屑病患者的嗅觉分数显著更低（p<0.001）。在50例银屑病患者中，40例（80%）嗅觉减退。我们发现TDI与PASI之间呈负相关（r = -0.34，p = 0.014）。发现中度至重度银屑病患者（PASI评分>10）的TDI分数显著低于轻度银屑病患者（PASI≤10）（p<0.001）。银屑病患者中的嗅觉功能障碍可被视为与其他炎症性疾病一样的一种合并症。医生在临床实践中评估银屑病患者时应意识到嗅觉损害。
